Plain-English translation of NCT06728228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study tests a procedure called amnioinfusion—injecting sterile fluid into the amniotic sac around the baby—to help fetuses with severe kidney failure develop their lungs properly. Normally, amniotic fluid is essential for lung growth, but babies with kidney failure produce little or no fluid, putting their lungs at serious risk. This treatment aims to restore fluid levels and improve the baby's chances of survival after birth.
Fetal kidney failure is a life-threatening condition that prevents normal amniotic fluid production, which stops the baby's lungs from developing properly. Without enough fluid, babies are at extreme risk of death shortly after birth. Early research suggests amnioinfusion may improve survival rates, and this trial will confirm whether this treatment is safe and effective.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive serial amnioinfusion procedures (where sterile fluid is injected into the amniotic sac as needed) plus routine prenatal care, or to receive comfort care and expectant management without the procedure. You will be followed closely by the Fetal Care Center team through pregnancy and delivery at Medical City Dallas, with ongoing consultations with kidney, newborn, and transplant specialists. After birth, your baby will receive care at the hospital until you are discharged, and the study will track your baby's survival and health outcomes over time.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States